BioCentury
ARTICLE | Targets & Mechanisms

More druggable than MYC

July 12, 2012 7:00 AM UTC

A Fred Hutchinson Cancer Research Center group has used a cell-based screen to identify 12 potential therapeutic targets in MYC-driven cancers that could be more druggable than MYC.1 The researchers hope to find an industry or academic partner to help develop inhibitors of some of the targets.

Aberrant overexpression of c-Myc (MYC) occurs in a variety of cancers. For example, 50% of ovarian cancers and 30% of hepatocellular carcinomas are driven by MYC overexpression.2,3...